Similar Items: Efficacy, Safety, and Prognostic Factors of Dalpiciclib Combined with Endocrine Therapy After Progression on CDK4/6 Inhibitors in Patients with HR+/HER2- Advanced Breast Cancer: A Retrospective Study
- Clinical Efficacy and Security Analysis of CDK4/6 Inhibitors Combined with ET in Patients with HR+HER2− Advanced Breast Cancer
- Capecitabine versus Paclitaxel After CDK4/6 Inhibitor Progression in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study
- CircCDK6 Regulates Stemness Maintenance and Cisplatin Resistance in Lung Adenocarcinoma via the Wnt/β-Catenin Signaling Pathway
- A Structured Classification of Pyrotinib-Containing Neoadjuvant Regimens for HER2-Positive Breast Cancer: Efficacy, Safety, and Regimen Selection
- The Impact of Androgen Receptor Expression on Neoadjuvant Therapy in HER2-Positive Breast Cancer
- Artificial Intelligence-Driven Quantitative HER2 Scoring and Spatial Bystander Effect Modeling for ADC Response Stratification in HER2-Low Breast Cancer